{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:22Z","timestamp":1793215102063,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2018YFC1002804"],"award-info":[{"award-number":["2018YFC1002804"]}]},{"name":"National Key Research and Development Program of China","award":["2016YFC1000600"],"award-info":[{"award-number":["2016YFC1000600"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771618"],"award-info":[{"award-number":["81771618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971356"],"award-info":[{"award-number":["81971356"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873817"],"award-info":[{"award-number":["81873817"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder with the disorders of estrogen(E2) and progesterone(P) secretion. The purpose of this study was to evaluate the association between the progesterone level or progesterone\/estradiol(P\/E2) ratio on human chorionic gonadotropin (hCG) trigger day and the outcome of in vitro fertilization in PCOS patients and explore the value of progesterone and P\/E2 ratio for predicting the clinical pregnancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The clinical data of 1254 PCOS patients who satisfied the inclusion criteria were retrospectively analyzed, including baseline characteristics such as age, body mass index, basal sex hormone levels, et al., as well as ovarian stimulation data and clinic outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of follicles larger than 14\u2009mm in diameter (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001) and retrieved oocytes (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001) was greater in the high progesterone group (progesterone\u00a0\u2265\u00a00.92\u2009ng\/mL). In the high P\/E2 group(P\/E2 ratio\u2009\u2265\u20090.3), the number of follicles larger than 14\u2009mm in diameter (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001) and retrieved oocytes (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001), as well as the rate of high-quality embryos (<jats:italic>P<\/jats:italic>\u2009=\u20090.040) were significantly decreased. In ultralong GnRH agonist protocol, the implantation rate(<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001), hCG positive rate (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001), clinical pregnancy rate (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001) and live birth rate (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001) were all significantly higher than long GnRH agonist protocol and GnRH antagonist protocol. The clinical pregnancy rate of high progesterone group was significantly lower than that of low progesterone group in ultralong GnRH agonist (<jats:italic>P<\/jats:italic>\u2009=\u20090.008). The progesterone level could be used as an indicator to predict the positive clinical pregnancy (long GnRH agonist: <jats:italic>P<\/jats:italic>\u00a0=\u20090.001; ultralong GnRH agonist: <jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.001) except in cycles using GnRH antagonist (<jats:italic>P<\/jats:italic>\u00a0=\u20090.169). In the ultralong GnRH agonist, the value of progesterone level in the prediction of clinical pregnancy was significantly higher than that of the P\/E2 ratio (<jats:italic>P<\/jats:italic>\u00a0=\u20090.021).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In PCOS patients, the progesterone level is associated with clinical pregnancy rate while P\/E2 ratio is not. In subgroup analysis using three different COS protocols, a significant association between progesterone level and clinical pregnancy rate can be observed in the long GnRH agonist protocol and ultralong GnRH agonist protocol. The progesterone level is significantly better than the P\/E2 ratio in predicting the pregnancy outcome of PCOS patients, especially in ultralong GnRH agonist cycles.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-021-00862-6","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:27:33Z","timestamp":1639196853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Exploration of the value of progesterone and progesterone\/estradiol ratio on the hCG trigger day in predicting pregnancy outcomes of PCOS patients undergoing IVF\/ICSI: a retrospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Yiqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2017.06.011","volume":"130","author":"D Macut","year":"2017","unstructured":"Macut D, Bjekic-Macut J, Rahelic D, et al. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017;130:163\u201370.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"862_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/humupd\/dmw025","volume":"22","author":"AH Balen","year":"2016","unstructured":"Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687\u2013708.","journal-title":"Hum Reprod Update"},{"key":"862_CR3","unstructured":"Rasquin Leon LI, Mayrin JV. Polycystic Ovarian Disease. StatPearls. Treasure Island 2021."},{"key":"862_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.575337","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Mo M, Xiao S, et al. Pregnancy outcomes of women with polycystic ovary syndrome for the first in vitro fertilization treatment: a retrospective cohort study with 7678 patients. Front Endocrinol (Lausanne). 2020;11:575337.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"862_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12958-021-00802-4","volume":"19","author":"X Bai","year":"2021","unstructured":"Bai X, Zheng L, Li D, et al. Research progress of endometrial receptivity in patients with polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol. 2021;19(1):122.","journal-title":"Reprod Biol Endocrinol"},{"issue":"4","key":"862_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/09513599509160465","volume":"9","author":"Y Zalel","year":"1995","unstructured":"Zalel Y, Orvieto R, Ben-Rafael Z, et al. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynecol Endocrinol. 1995;9(4):313\u20135.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"862_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/S0015-0282(16)58337-X","volume":"65","author":"A Pellicer","year":"1996","unstructured":"Pellicer A, Valbuena D, Cano F, et al. Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril. 1996;65(6):1190\u20135.","journal-title":"Fertil Steril"},{"issue":"4","key":"862_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.rbmo.2010.05.018","volume":"21","author":"R Fleming","year":"2010","unstructured":"Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod BioMed Online. 2010;21(4):446\u20139.","journal-title":"Reprod BioMed Online"},{"issue":"9","key":"862_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/humrep\/dei069","volume":"20","author":"EM Kolibianakis","year":"2005","unstructured":"Kolibianakis EM, Bourgain C, Papanikolaou EG, et al. Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod. 2005;20(9):2453\u20136.","journal-title":"Hum Reprod"},{"issue":"12","key":"862_CR10","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Andersen","year":"2006","unstructured":"Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217\u201327.","journal-title":"Hum Reprod"},{"key":"862_CR11","doi-asserted-by":"crossref","unstructured":"Bosch E, Vidal C, Labarta E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study. Hum Reprod 2008;23(10):2346\u20132351.","DOI":"10.1093\/humrep\/den220"},{"issue":"6","key":"862_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.fertnstert.2003.07.002","volume":"80","author":"E Bosch","year":"2003","unstructured":"Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80(6):1444\u20139.","journal-title":"Fertil Steril"},{"issue":"5","key":"862_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.rbmo.2012.02.003","volume":"24","author":"Z Wu","year":"2012","unstructured":"Wu Z, Li R, Ma Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles. Reprod BioMed Online. 2012;24(5):511\u201320.","journal-title":"Reprod BioMed Online"},{"issue":"11","key":"862_CR14","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/humrep\/dep290","volume":"24","author":"D Kyrou","year":"2009","unstructured":"Kyrou D, Popovic-Todorovic B, Fatemi HM, et al. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH\/GnRH antagonist? Hum Reprod. 2009;24(11):2902\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"862_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10815-010-9393-8","volume":"27","author":"AM Elnashar","year":"2010","unstructured":"Elnashar AM. Progesterone rise on the day of HCG administration (premature luteinization) in IVF: an overdue update. J Assist Reprod Genet. 2010;27(4):149\u201355.","journal-title":"J Assist Reprod Genet"},{"issue":"8","key":"862_CR16","first-page":"2696","volume":"10","author":"M Hu","year":"2018","unstructured":"Hu M, Li J, Zhang Y, et al. Endometrial progesterone receptor isoforms in women with polycystic ovary syndrome. Am J Transl Res. 2018;10(8):2696\u2013705.","journal-title":"Am J Transl Res"},{"key":"862_CR17","doi-asserted-by":"crossref","unstructured":"Jakimiuk AJ, Weitsman SR, Brzechffa PR, et al. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod 1998 Jan;4(1):1\u20138.","DOI":"10.1093\/molehr\/4.1.1"},{"issue":"3","key":"862_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0015-0282(97)00561-X","volume":"69","author":"JS Younis","year":"1998","unstructured":"Younis JS, Haddad S, Matilsky M, et al. Premature luteinization: could it be an early manifestation of low ovarian reserve? Fertil Steril. 1998;69(3):461\u20135.","journal-title":"Fertil Steril"},{"issue":"4","key":"862_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.fertnstert.2008.08.024","volume":"92","author":"FK Lee","year":"2009","unstructured":"Lee FK, Lai TH, Lin TK, et al. Relationship of progesterone\/estradiol ratio on day of hCG administration and pregnancy outcomes in high responders undergoing in vitro fertilization. Fertil Steril. 2009;92(4):1284\u20139.","journal-title":"Fertil Steril"},{"issue":"2","key":"862_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.fertnstert.2008.06.036","volume":"92","author":"TH Lai","year":"2009","unstructured":"Lai TH, Lee FK, Lin TK, et al. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol. Fertil Steril. 2009;92(2):508\u201314.","journal-title":"Fertil Steril"},{"issue":"2","key":"862_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1447-0756.2003.00166.x","volume":"30","author":"HT Oz\u00e7akir","year":"2004","unstructured":"Oz\u00e7akir HT, Levi R, Tavmergen E, et al. Premature luteinization defined as progesterone estradiol ratio >1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin-releasing hormone agonist cycles. J Obstet Gynaecol Res. 2004;30(2):100\u20134.","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"862_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1028-4559(08)60075-3","volume":"47","author":"YC Ou","year":"2008","unstructured":"Ou YC, Lan KC, Chang SY, et al. Increased progesterone\/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone. Taiwan J Obstet Gynecol. 2008;47(2):168\u201374.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"862_CR23","doi-asserted-by":"crossref","unstructured":"Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19(1):41\u201347.","DOI":"10.1093\/humrep\/deh098"},{"issue":"6","key":"862_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/humrep\/dei474","volume":"21","author":"MA Melo","year":"2006","unstructured":"Melo MA, Meseguer M, Garrido N, et al. The significance of premature luteinization in an oocyte-donation programme. Hum Reprod. 2006;21(6):1503\u20137.","journal-title":"Hum Reprod"},{"issue":"5","key":"862_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1472-6483(10)60475-0","volume":"16","author":"R Li","year":"2008","unstructured":"Li R, Qiao J, Wang L, et al. Serum progesterone concentration on day of HCG administration and IVF outcome. Reprod BioMed Online. 2008;16(5):627\u201331.","journal-title":"Reprod BioMed Online"},{"key":"862_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1196\/annals.1290.042","volume":"997","author":"G Nikas","year":"2003","unstructured":"Nikas G, Makrigiannakis A. Endometrial pinopodes and uterine receptivity. Ann N Y Acad Sci. 2003;997:120\u20133.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"862_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/humrep\/der126","volume":"26","author":"E Labarta","year":"2011","unstructured":"Labarta E, Mart\u00ednez-Conejero JA, Alam\u00e1 P, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011;26(7):1813\u201325.","journal-title":"Hum Reprod"},{"issue":"3","key":"862_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/humrep\/14.3.601","volume":"14","author":"N Doldi","year":"1999","unstructured":"Doldi N, Marsiglio E, Destefani A, et al. Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Hum Reprod. 1999;14(3):601\u20135.","journal-title":"Hum Reprod"},{"key":"862_CR29","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez F, Coroleu B, Clua E, et al. Serum progesterone concentrations on the day of HCG administration cannot predict pregnancy in assisted reproduction cycles. Reprod BioMed Online 2004 Feb;8(2):183\u2013190.","DOI":"10.1016\/S1472-6483(10)60514-7"},{"issue":"6","key":"862_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.fertnstert.2003.10.039","volume":"81","author":"AS Blazar","year":"2004","unstructured":"Blazar AS, Hogan JW, Frankfurter D, et al. Serum estradiol positively predicts outcomes in patients undergoing in vitro fertilization. Fertil Steril. 2004;81(6):1707\u20139.","journal-title":"Fertil Steril"},{"issue":"1","key":"862_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/09513590.2017.1336217","volume":"34","author":"R Arora","year":"2018","unstructured":"Arora R, Chan C, Ye XY, et al. Progesterone, progesterone\/estradiol and ART outcomes in day-5 transfer cycles. Gynecol Endocrinol. 2018;34(1):59\u201363.","journal-title":"Gynecol Endocrinol"},{"key":"862_CR32","doi-asserted-by":"crossref","unstructured":"Fauser BC, Diedrich K, Devroey P, et al. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008;14(1):1\u201314.","DOI":"10.1093\/humupd\/dmm034"},{"issue":"4","key":"862_CR33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1472-6483(10)60633-5","volume":"13","author":"MH van der Gaast","year":"2006","unstructured":"van der Gaast MH, Eijkemans MJ, van der Net JB, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod BioMed Online. 2006;13(4):476\u201380.","journal-title":"Reprod BioMed Online"},{"key":"862_CR34","doi-asserted-by":"crossref","unstructured":"Broer SL, Dolleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011 Jan-Feb;17(1):46\u201354.","DOI":"10.1093\/humupd\/dmq034"},{"issue":"3","key":"862_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/jc.2017-01186","volume":"103","author":"C Moretti","year":"2018","unstructured":"Moretti C, Guccione L, Di Giacinto P, et al. Combined Oral contraception and Bicalutamide in polycystic ovary syndrome and severe Hirsutism: a double-blind randomized controlled trial. J Clin Endocrinol Metab. 2018;103(3):824\u201338.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-021-00862-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:28:30Z","timestamp":1639196910000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-021-00862-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1186\/s12958-021-00862-6","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval number: WDRY2019-K077.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}